Director/PDMR Share Dealings

    September 30, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")
    announces that Ordinary Shares ("Shares") and American Depositary Shares
    ("ADSs") of the Company, as set out below, have been acquired today for the
    Non-Executive Directors, being the part of their total fees that are paid in
    shares for the period of service from July 1 to September 30, 2015.

                       Type of Security (1)    Number of Shares/ADSs  
                                                                      
    Dominic Blakemore  Shares                              129        
                                                                      
    Olivier Bohuon     Shares                              127        
                                                                      
    William Burns      Shares                              155        
                                                                      
    Dr. Steven Gillis  ADSs                                 52        
                                                                      
    Dr. David Ginsburg ADSs                                 45        
                                                                      
    David Kappler      Shares                              151        
                                                                      
    Susan Kilsby       ADSs                                154        
                                                                      
    Sara Mathew        ADSs                                 16        
                                                                      
    Anne Minto         Shares                              154        

    (1)                One ADS is equal to three Shares

    The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ
    respectively at £44.98 per Share and $204.1653 per ADS.

    This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a)
    of the Disclosure and Transparency Rules.

    Tony Guthrie
    Deputy Company Secretary

    For further information please contact:

    Investor Relations                                                            
                                                                                  
    Matthew Osborne                       mattosborne@shire.com +1 781 482 9502   
                                                                                  
    Sarah Elton-Farr                      seltonfarr@shire.com  +44 1256 894157   


     

    NOTES TO EDITORS

    Shire enables people with life-altering conditions to lead better lives.

    Our strategy is to focus on developing and marketing innovative specialty
    medicines to meet significant unmet patient needs.

    We focus on providing treatments in Rare Diseases, Neuroscience,
    Gastrointestinal and Internal Medicine and we are developing treatments for
    symptomatic conditions treated by specialist physicians in other targeted
    therapeutic areas, such as Ophthalmics.

    http://www.shire.com/